Frost & Sullivan Independent Equity Research

RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.


Company: RedHill Biopharma        

Sector: Pharmaceuticals

Report type: Quarterly Report

Published on: November 27, 2017

RedHill research articles:

Close Menu
Font Resize